about
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic reviewAdjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patientsEvaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients.MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerProtein expression patterns of cell cycle regulators in operable breast cancer.Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy.The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer.
P50
Q33662162-68EE97E0-2827-4AE5-A9F8-0B1C057D9582Q34010867-0A9F4E88-0BFE-406F-A199-E41B4931211BQ35193385-FD6FE0D7-EAA2-4322-9865-51A3468243E5Q35663809-8F442236-9146-4F66-8D05-2DA1A00557F5Q36085452-8EC2879B-A81A-4681-9F92-A7F037906B3BQ36907273-CF8FC016-5BEC-42BC-A9DE-8EAA1062093FQ38630291-A90B88E7-033E-4697-980B-776E6262DC1CQ38699879-AF42CF2B-6EB8-41AB-8640-6FDD27268FECQ38759878-4500271F-D625-44B3-8CB3-1E4C6CC01C66Q39855748-FC85526F-69AC-4A74-904C-69F43421EC83
P50
description
wetenschapper
@nl
name
Gerasimos Aravantinos
@en
Gerasimos Aravantinos
@nl
type
label
Gerasimos Aravantinos
@en
Gerasimos Aravantinos
@nl
prefLabel
Gerasimos Aravantinos
@en
Gerasimos Aravantinos
@nl
P31
P496
0000-0002-2106-1713